Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and marketing innovative drug therapies. While it boasts impressive profitability metrics, including a gross margin of 52.5% and an extraordinary net margin of 147.2%, its liquidity ratios are concerning, with both the current and quick ratios at 0.03, indicating potential cash flow issues. The low market cap of $663.17K and stock price of $0.01 suggest a significant disconnect between its strong margins and overall valuation, raising questions about its financial stability and growth prospects.
Loading financial metrics...
Company has $14K in cash but burned $29K last quarter. At this burn rate, only 0.5 quarters of runway remain without additional financing.
Company posted a loss of $-656K over the last year, representing 71.5% of revenue.
Debt of $6.0M is 435.0x the company's cash position of $14K.
Exceptional revenue growth of 264.8% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 25.6 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 662.0pp, demonstrating strong operational leverage.
Both gross margin (+25.6pp) and operating margin (+662.0pp) are expanding simultaneously, indicating the company is scaling profitably.
Strong gross margin of 56.9% reflects healthy unit economics.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q3 (September 30, 2025)